RA Capital Management 13F holdings, Q1 2016
Holdings as of March 31, 2016 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 42 US equity positions worth $782.3m in its Q1 2016 13F filing. The largest position was WVE at 12.6% of the reported book, followed by ACHILLION PHARMACEUTICALS INC and AXOVANT SCIENCES LTD. Against the Q4 2015 filing, it opened 7 new positions, added to 12 and reduced 6 among the top 42 holdings.
What did RA Capital Management own in Q1 2016? Top 42 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2015 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 12.6% | $98.4m | 7,088,651 | 0% | held |
| 2 | ACHILLION PHARMACEUTICALS INC | 11.9% | $92.9m | 12,033,220 | 7% | added | |
| 3 | AXOVANT SCIENCES LTD | 7.3% | $57.4m | 5,000,000 | 0% | held | |
| 4 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 6.4% | $49.8m | 2,627,719 | 2% | added |
| 5 | NKTR NEKTAR THERAPEUTICS | Healthcare | 5.6% | $43.7m | 3,178,854 | – | new |
| 6 | ASND ASCENDIS PHARMA A S | Healthcare | 5.1% | $40.1m | 2,161,366 | 29% | added |
| 7 | TGTX TG THERAPEUTICS INC | Healthcare | 4.9% | $38.6m | 4,531,714 | 61% | added |
| 8 | AVEXIS INC | 4.7% | $37.1m | 1,361,582 | – | new | |
| 9 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 3.5% | $27.0m | 1,272,048 | 0% | held |
| 10 | ZOGENIX INC | 2.9% | $22.6m | 2,451,237 | 9% | added | |
| 11 | ARENA PHARMACEUTICAL S INC | 2.4% | $18.4m | 9,364,105 | 7% | added | |
| 12 | ARDX ARDELYX INC | Healthcare | 2.3% | $17.9m | 2,300,481 | 303% | added |
| 13 | AIMT AIMMUNE THERAPEUTICS INC | 2.2% | $17.5m | 1,292,940 | 64% | added | |
| 14 | CELATOR PHARMACEUTICALS INC | 2.0% | $15.6m | 1,414,114 | – | new | |
| 15 | AQUINOX PHARMACEUTICALS INC | 1.9% | $14.9m | 1,691,977 | 4% | added | |
| 16 | CIDARA THERAPEUTICS INC | 1.9% | $14.9m | 1,174,219 | 0% | held | |
| 17 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 1.7% | $13.4m | 2,212,036 | 0% | held |
| 18 | ACORDA THERAPEUTICS INC | 1.7% | $13.2m | 498,159 | – | new | |
| 19 | DICERNA PHARMACEUTICALS INC | 1.7% | $13.0m | 2,428,571 | 0% | held | |
| 20 | PROTEON THERAPEUTICS INC | 1.6% | $12.6m | 1,626,931 | 10% | added | |
| 21 | STRONGBRIDGE BIOPHARMA PLC | 1.6% | $12.3m | 2,690,702 | 0% | held | |
| 22 | DIMENSION THERAPEUTICS INC | 1.5% | $12.1m | 1,548,033 | 42% | added | |
| 23 | ALCOBRA LTD | 1.5% | $11.5m | 3,032,911 | 0% | held | |
| 24 | VITAE PHARMACEUTICALS INC | 1.3% | $10.4m | 1,575,000 | 390% | added | |
| 25 | COLL COLLEGIUM PHARMACEUTICAL INC | Healthcare | 1.1% | $8.8m | 486,557 | -43% | reduced |
| 26 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 1.1% | $8.5m | 2,989,795 | -3% | reduced |
| 27 | NTRA NATERA INC | Healthcare | 1.0% | $7.5m | 783,520 | 0% | held |
| 28 | REGULUS THERAPEUTICS INC | 0.9% | $7.2m | 1,045,119 | -70% | reduced | |
| 29 | AGILE THERAPEUTICS INC | 0.8% | $6.6m | 1,064,217 | – | new | |
| 30 | ONC BEIGENE LTD | Healthcare | 0.6% | $5.0m | 170,000 | – | new |
| 31 | TENX TENAX THERAPEUTICS INC | 0.6% | $4.9m | 2,389,700 | 0% | held | |
| 32 | EIGER BIOPHARMACEUTICALS INC | 0.6% | $4.9m | 291,700 | – | new | |
| 33 | ZYNERBA PHARMACEUTICALS INC | 0.6% | $4.8m | 507,191 | 0% | held | |
| 34 | PRONAI THERAPEUTICS INC | 0.5% | $4.1m | 604,982 | 0% | held | |
| 35 | 2GT APPLIED GENETIC TECHNOL CORP | 0.4% | $3.3m | 236,059 | 0% | held | |
| 36 | ARCA BIOPHARMA INC | 0.3% | $2.7m | 778,211 | 0% | held | |
| 37 | AKTX AKARI THERAPEUTICS PLC | 0.3% | $2.6m | 257,721 | -2% | reduced | |
| 38 | NIVALIS THERAPEUTICS INC | 0.3% | $2.6m | 612,863 | 0% | held | |
| 39 | NEURODERM LTD | 0.3% | $2.0m | 144,671 | 0% | held | |
| 40 | 2655787D BLUEPRINT MEDICINES CORP | 0.1% | $1.0m | 56,442 | -94% | reduced | |
| 41 | DERMA SCIENCES INC | 0.0% | $252.0k | 81,239 | -87% | reduced | |
| 42 | AMPLIPHI BIOSCIENCES CORP | 0.0% | $211.0k | 53,600 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.